Q-omics provides the consensus-scored MIR1268B profile across patient tissues and cancer cell-line models. MIR1268B expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MIR1268B is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, MIR1268B RNA expression shows 6,412 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, LUAD, and STAD as cancer lineages where MIR1268B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1268B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1268B survival associations across molecular data types. MIR1268B RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1268B RNA expression–survival associations across cancer types. High MIR1268B expression shows unfavorable associations in THCA, COAD, READ, UCEC, PAAD and UVM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for MIR1268B RNA expression.
This table summarizes MIR1268B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1268B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1268B shows lower tumor expression in THCA and higher tumor expression in LUAD and LIHC. The LUAD box plot shows higher MIR1268B RNA expression in tumor versus normal tissue (log2 FC = +0.241, t-test p = .004).
This table shows molecular features associated with MIR1268B in patient tissues and cancer cell lines. In patient samples, MIR1268B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
